Log in

Lipocine Stock Price, News & Analysis (NASDAQ:LPCN)

$2.78
+0.06 (+2.21 %)
(As of 10/14/2019 04:32 AM ET)
Today's Range
$2.73
Now: $2.78
$2.86
50-Day Range
$2.64
MA: $2.89
$3.39
52-Week Range
$1.04
Now: $2.78
$3.45
Volume48,903 shs
Average Volume95,016 shs
Market Capitalization$69.06 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value$0.44 per share

Profitability

Net Income$-11,660,000.00

Miscellaneous

Employees10
Market Cap$69.06 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.


Lipocine (NASDAQ:LPCN) Frequently Asked Questions

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) announced its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.07. View Lipocine's Earnings History.

When is Lipocine's next earnings date?

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Lipocine.

What price target have analysts set for LPCN?

2 brokers have issued twelve-month price targets for Lipocine's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Lipocine's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Price Targets for Lipocine.

What is the consensus analysts' recommendation for Lipocine?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lipocine.

Has Lipocine been receiving favorable news coverage?

Headlines about LPCN stock have trended negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lipocine earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Lipocine.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 274,600 shares, an increase of 20.4% from the August 30th total of 228,000 shares. Based on an average daily trading volume, of 146,700 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.2% of the shares of the stock are short sold. View Lipocine's Current Options Chain.

Who are some of Lipocine's key competitors?

What other stocks do shareholders of Lipocine own?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
  • Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
  • Logan Morse, VP of Sales, Marketing & Operations (Age 49)
  • Nachiappan Chidambaram, VP of Product Devel. (Age 50)
  • Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $2.78.

How big of a company is Lipocine?

Lipocine has a market capitalization of $69.06 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.

What is Lipocine's official website?

The official website for Lipocine is http://www.lipocine.com/.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]


MarketBeat Community Rating for Lipocine (NASDAQ LPCN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel